Citation Impact
Citing Papers
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
2000 Standout
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
2000 Standout
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
2003 Standout
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
2004 StandoutScience
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Human Multidrug Resistance Associated Protein 4 Confers Resistance to Camptothecins
2005
Gastric cancer
2016 Standout
Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin
2003
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
1998
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
2011
Pancreatic cancer
2004 Standout
Effect of Adenovirus-Mediated Expression of Sonic Hedgehog Gene on Hair Regrowth in Mice With Chemotherapy-Induced Alopecia
2001
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
2008
Role of Gemcitabine in Breast Cancer Management: An Update
2006
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
2003
Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001
2002
3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells
2012
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
1997
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer
2002
Safety and antitumor activity of recombinant soluble Apo2 ligand
1999 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches
2004
Gemcitabine in locally advanced and/or metastatic bladder cancer
2000
Papillomaviruses and cancer: from basic studies to clinical application
2002 StandoutNobel
The growing impact of click chemistry on drug discovery
2003 StandoutNobel
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer
2003
Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization
2007
Oesophageal carcinoma
2013 Standout
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
1996
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1
2004
Sickle-cell disease
2010 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer
1999
Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer
2005
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma
2001
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
2006
Gastric cancer
2020 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Pathobiology of chemotherapy-induced hair loss
2013
Maintenance Therapy With Continuous or Switch Strategy in Advanced Non-small Cell Lung Cancer
2011
Topoisomerase I inhibitors: Review and update
1997
Role of gemcitabine in cancer therapy
2005
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial
2000
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
2000 Standout
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
Small-cell lung cancer
2005
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer
2005
Retinoids: present role and future potential
1999
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
2010
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Pharmacologic Modulation of Fetal Hemoglobin
2001
Single agent maintenance therapy for advanced stage non-small cell lung cancer: A meta-analysis
2012
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
2003 Standout
Anemia of Chronic Disease
2005 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
2005 Standout
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma
2001
A multicenter, Phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
1999
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Tumour stem cells and drug resistance
2005 Standout
Retinoic acid and interferon combination studies in human cancer
1993
Electrospinning and Electrospun Nanofibers: Methods, Materials, and Applications
2019 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Molecular Modeling Studies of the DNA−Topoisomerase I Ternary Cleavable Complex with Camptothecin
1998 StandoutNobel
Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice
2012
Recent Natural Products Based Drug Development: A Pharmaceutical Industry Perspective
1998
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
2005 Standout
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
2001
Combination of Oxaliplatin Plus Irinotecan in Patients With Gastrointestinal Tumors: Results of Two Independent Phase I Studies With Pharmacokinetics
1999
Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent.
2000
NCCN Task Force Report: Management of Neuropathy in Cancer
2009
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
2004 Standout
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
2003 Standout
Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study
1999
Pharmacological Effects of Formulation Vehicles
2003
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer
2008
Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review
2007
Impact of Natural Products on Developing New Anti-Cancer Agents
2009 Standout
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
2001 Standout
Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer
1999
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
2007 Standout
Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With Cisplatin
1999
A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.
2002
Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer
1999
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Second-line chemotherapy for non-small cell lung cancer
2002
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
DNA Topoisomerases: Structure, Function, and Mechanism
2001 Standout
Dose translation from animal to human studies revisited
2007 Standout
Works of David Rinaldi being referenced
Randomized double-blind phase 2 study evaluating sameday vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (tac) in women with early stage and advanced breast cancer
2004
Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5-FU and Radiation Therapy in Locoregional Esophageal Cancer
2003
Phase II Trial of Docetaxel for Cholangiocarcinoma
1999
Phase II study of 13-cis-retinoic acid and interferon-α2a in patients with advanced squamous cell lung cancer
1993
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
2001
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
1999
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
1996
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium
1996
Peripheral neuropathy secondary to docetaxel (Taxotere)
1996
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
1998
A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia
1999
A Phase I–II Trial of Topotecan and Gemcitabine in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer (LOA-3)
2001
Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
1995
O-107 Adjuvant targeted therapy in unresectable lung cancer: The results of two randomized placebo-controlled trials of BAY 12-9566, a matrix metalloproteinase inhibitor (MMPI)
2003
Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation
2003
Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer
2003
Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies
1999
A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea
1998